

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported)**  
February 4, 2014

---

**Pacific Biosciences of California, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34899**  
(Commission  
File Number)

**16-1590339**  
(IRS Employer  
Identification No.)

**1380 Willow Road**  
**Menlo Park, California 94025**  
(Address of principal executive offices, including zip code)

**(650) 521-8000**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On February 4, 2014, Pacific Biosciences of California, Inc. announced its financial results for the quarter ended December 31, 2013. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.

This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

99.1 Press Release dated February 4, 2014 titled "Pacific Biosciences of California, Inc. Announces Fourth Quarter 2013 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Pacific Biosciences of California, Inc.**

By: \_\_\_\_\_ /s/ Brian B. Dow

**Brian B. Dow**

**Vice President and Principal Accounting Officer**

Date: February 4, 2014

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated February 4, 2014 titled "Pacific Biosciences of California, Inc. Announces Fourth Quarter 2013 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).

**Pacific Biosciences of California, Inc. Announces  
Fourth Quarter 2013 Financial Results**

**Menlo Park, Calif.** – February 4, 2014 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the fourth quarter ended December 31, 2013.

Total revenue for the fourth quarter of 2013 totaled \$9.1 million, compared to \$5.9 million for the fourth quarter of 2012. Fourth quarter revenue in 2013 reflects the installation of five PacBio RS II systems, compared to five PacBio RS systems in the fourth quarter of 2012. Total revenue for the fourth quarter of 2013 also included \$1.7 million of revenue recognized pursuant to a development agreement the Company entered into with Roche Diagnostics at the end of the third quarter of 2013. The Company booked orders for nine PacBio RS II instruments during the fourth quarter and ended the quarter with 13 instruments in backlog.

Gross profit for the fourth quarter of 2013 was \$3.2 million, resulting in a gross margin of 34.9%, compared to gross profit of \$0.6 million and a gross margin of 10.7% for the fourth quarter of 2012. Gross profit for the fourth quarter in 2013 included \$1.7 million of gross profit recognized pursuant to the development agreement with Roche Diagnostics.

Operating expenses totaled \$20.2 million for the fourth quarter of 2013, compared to \$22.3 million for the fourth quarter of 2012. Operating expenses for the fourth quarter of 2013 and 2012 included \$2.5 million of non-cash stock-based compensation, respectively.

The net loss for the fourth quarter of 2013 was \$17.2 million, compared to \$21.7 million for the fourth quarter of 2012.

Cash and investments at December 31, 2013 totaled \$112.5 million compared to \$100.6 million at December 31, 2012.

#### **Quarterly Conference Call Information**

Management will host a quarterly conference call to discuss its fourth quarter 2013 results today at 4:30pm Eastern Time / 1:30pm Pacific Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330. The call will be webcast live and will be available for replay at Pacific Biosciences' website at <http://investor.pacificbiosciences.com/>.

#### **About Pacific Biosciences**

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers the PacBio® RS II Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Sequencing technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

#### **Contact:**

Trevin Rard  
650.521.8450  
[ir@pacificbiosciences.com](mailto:ir@pacificbiosciences.com)

**Pacific Biosciences of California, Inc.**  
**Unaudited Consolidated Statement of Operations**  
*(amounts in thousands, except per share amounts)*

	<b>Quarter Ended December 31,</b>	
	<b>2013</b>	<b>2012</b>
<b>Revenue:</b>		
Product revenue	\$ 5,791	\$ 4,279
Service and other revenue	1,647	1,599
Revenue from development agreement	1,696	—
Total revenue	9,134	5,878
<b>Cost of revenue:</b>		
Cost of product revenue	4,568	3,847
Cost of service and other revenue	1,377	1,404
Total cost of revenue	5,945	5,251
Gross profit	3,189	627
<b>Operating expense:</b>		
Research and development	11,133	11,652
Sales, general and administrative	9,060	10,669
Total operating expense	20,193	22,321
<b>Operating loss</b>	(17,004)	(21,694)
Interest expense	(693)	(67)
Other income, net	466	92
<b>Net loss</b>	\$ (17,231)	\$ (21,669)
<b>Basic and diluted net loss per share</b>	\$ (0.26)	\$ (0.39)
Shares used in computing basic and diluted net loss per share	66,190	56,166

**Pacific Biosciences of California, Inc.**  
**Unaudited Consolidated Statement of Operations**  
*(amounts in thousands, except per share amounts)*

	<u>Year Ended December 31,</u>	
	<u>2013</u>	<u>2012</u>
Revenue:		
Product revenue	\$ 20,039	\$ 20,089
Service and other revenue	6,446	5,894
Revenue from development agreement	1,696	—
Total revenue	<u>28,181</u>	<u>25,983</u>
Cost of Revenue:		
Cost of product revenue	15,706	18,796
Cost of service and other revenue	6,056	6,247
Total cost of revenue	<u>21,762</u>	<u>25,043</u>
Gross profit	6,419	940
Operating Expense:		
Research and development	45,217	47,623
Sales, general and administrative	38,745	47,655
Total operating expense	<u>83,962</u>	<u>95,278</u>
Operating loss	(77,543)	(94,338)
Interest expense	(2,478)	(274)
Other income, net	728	147
Net loss	<u>\$ (79,293)</u>	<u>\$ (94,465)</u>
Basic and diluted net loss per share	<u>\$ (1.26)</u>	<u>\$ (1.69)</u>
Shares used in computing basic and diluted net loss per share	<u>62,784</u>	<u>55,733</u>

**Pacific Biosciences of California, Inc.**  
**Unaudited Condensed Consolidated Balance Sheets**  
*(amounts in thousands)*

	December 31, 2013	December 31, 2012
<b>Assets</b>		
Cash and investments	\$ 112,528	\$ 100,580
Accounts receivable	2,746	2,822
Inventory	10,050	9,592
Prepaid and other current assets	1,135	2,006
Property and equipment	9,236	14,329
Other long-term assets	490	354
<b>Total Assets</b>	<b>\$ 136,185</b>	<b>\$ 129,683</b>
<b>Liabilities and Stockholders' Equity</b>		
Accounts payable	\$ 1,717	\$ 2,988
Accrued and other current liabilities	9,797	8,377
Deferred service revenue	4,564	4,178
Deferred development revenue	33,304	—
Facility financing and other non-current liabilities	3,727	4,758
Financing derivative	549	—
Notes payable	13,347	—
Stockholders' equity	69,180	109,382
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 136,185</b>	<b>\$ 129,683</b>